TABLE 3.
Screen positive for migraine via the AMS/AMPP diagnostic migraine screening module and/or self‐reported medical diagnosis of migraine, stratified by monthly headache days (OVERCOME (US) 2018 migraine cohort; N = 21,143)
| Total | Monthly headache days | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0–3 | 4–7 | 8–14 | ≥15 | |||||||
| (N = 21,143) | (N = 12,299) | (N = 4070) | (N = 2291) | (N = 2483) | ||||||
| Migraine | N | % | N | % | N | % | N | % | N | % |
| AMS/AMPP module positive for migraine, yes | 19,888 | 94.1% | 11,414 | 92.8% | 3897 | 95.7% | 2201 | 96.1% | 2376 | 95.7% |
| SR‐MD of migraine, yes | 12,905 | 61.0% | 6812 | 55.4% | 2675 | 65.7% | 1556 | 67.9% | 1862 | 75.0% |
| SR‐MD, yes among AMS/AMPP positive, yes | 11,650 | 58.6% | 5927 | 51.9% | 2502 | 64.2% | 1466 | 66.6% | 1755 | 73.9% |
| AMS/AMPP positive, yes and SR‐MD, yes | 11,650 | 55.1% | 5927 | 48.2% | 2502 | 61.5% | 1466 | 64.0% | 1755 | 70.7% |
| AMS/AMPP positive, yes and SR‐MD, no | 8238 | 39.0% | 5487 | 44.6% | 1395 | 34.3% | 735 | 32.1% | 621 | 25.0% |
| AMS/AMPP positive, no and SR‐MD, yes | 1255 | 5.9% | 885 | 7.2% | 173 | 4.3% | 90 | 3.9% | 107 | 4.3% |
Abbreviations: AMPP, American Migraine Prevalence and Prevention; AMS, American Migraine Study; OVERCOME, ObserVational survey of the Epidemiology, tReatment and Care of MigrainE; SR‐MD, self‐reported medical diagnosis of migraine.